Command Palette

Search for a command to run...

Discover

Marty Makary Resigns as FDA Commissioner; Kyle Diamantas Named Acting Chief

Marty Makary Resigns as FDA Commissioner; Kyle Diamantas Named Acting Chief
View gallery

Marty Makary resigned as commissioner of the U.S. Food and Drug Administration on Tuesday, ending a 13‑month tenure marked by mass layoffs, policy whiplash and clashes with the Trump White House over issues ranging from vaping to abortion drugs politico +1. Kyle Diamantas, the agency’s food chief and a former corporate lawyer, was immediately tapped to serve as acting commissioner usatoday +1.

Makary’s exit followed weeks of speculation that President Donald Trump had approved a plan to remove him after repeated disagreements over flavored e‑cigarettes, vaccine messaging and the abortion pill mifepristone washingtonpost +1. Trump publicly called Makary “a great guy” and “a friend” while confirming he was out, but senior officials said Health and Human Services Secretary Robert F. Kennedy Jr. played a central role in the push to replace him usatoday +1. The shake‑up deepened concerns about instability at an agency still reeling from a 2025 restructuring that eliminated roughly 3,500 FDA and HHS positions usatoday.

A Turbulent Tenure Ends in a Vaping Fight

Reporting from multiple outlets pointed to the administration’s early‑May decision to greenlight fruit‑flavored nicotine vaping pods as a key flashpoint in Makary’s downfall politico +1. Makary had resisted pressure to allow such products, warning about youth appeal, before ultimately presiding over the authorization of the first fruity vapes in years, a move that angered public‑health advocates and did not fully satisfy pro‑vaping voices politico +1.

The vaping dispute came on top of battles over Makary’s approach to Covid and shingles vaccine safety communications and his handling of abortion pill regulations, which drew fire from anti‑abortion groups who accused him of moving too slowly to curb access to mifepristone nbcnews +1. “FDA Commissioner Makary should be fired immediately,” Marjorie Dannenfelser of Susan B. Anthony Pro‑Life America said days before his resignation, underscoring the political pressure from the right npr. Inside the agency, frequent turnover among senior science leaders and confusion over new fast‑track drug‑approval policies added to what one analyst described as the FDA’s “most uncertain” period in a decade for drugmakers and investors cbsnews.

Who Is Kyle Diamantas, and What Changes Now?

Diamantas joined the FDA in early 2025 to lead its human foods program after a career at law firms that represented major corporations, including infant‑formula maker Abbott during litigation over contaminated products usatoday. He does not have a medical degree and has previously said he would recuse himself for one year from matters involving former clients, a pledge that may limit his early authority over some high‑profile industry decisions usatoday. His elevation was signed off by the White House and HHS leadership, who are seeking a steadier hand and closer alignment with Kennedy’s priorities after what one official called months of “chaos” under Makary usatoday +1.

Public‑health advocates and some former FDA officials warned that the choice of a food‑policy lawyer as acting commissioner could tilt the agency toward industry and politically powerful constituencies such as the tobacco lobby and anti‑abortion activists politico +1. Trade groups representing biotech and pharmaceutical companies, while critical of the regulatory unpredictability under Makary, emphasized the need for “organizational strength and stability at the agency” rather than continued churn at the top cbsnews.

The Bigger Picture

Makary’s fall and Diamantas’s rapid promotion underscored how deeply partisan fights over vaping, vaccines and abortion have penetrated the FDA, long viewed as a technocratic regulator. The leadership change is likely to shape near‑term decisions on flavored e‑cigarettes, abortion‑pill access and the pace of drug approvals, with consequences for public health and billions of dollars in pharmaceutical and biotech investment politico +2. With trust in the agency already strained and morale bruised by layoffs and high‑profile resignations, the central question now is whether an acting commissioner with roots in food regulation and corporate law can steady the FDA—or whether the agency remains a battleground in the 2026 election year.